May 17 (Reuters) - Moderna (MRNA.O), opens new tab said on Friday the European Patent Office had upheld the validity of one of the company's key patents, a win in an ongoing COVID-19 vaccine ...

The Federal Circuit upheld a ruling that Moderna's COVID-19 vaccine does not infringe Alnylam's mRNA patents related to the SM-102 lipid used in Spikevax.

Moderna said Friday that the European Patent ... rival COVID-19 vaccines. Cambridge-based Moderna has been fighting Pfizer and BioNTech in the courts over the partners’ COVID shot, called ...

When a novel respiratory virus emerged and sparked global worries, Moderna responded with a new infectious disease division. The biotech’s scientists developed a messenger RNA vaccine that ...

Who knows, perhaps Genevant, with its billionaire hedge fund owner, or even little Arbutus, might have had a shot at COVID ... to dismiss Moderna's case, insisting that Moderna's patents are ...

Moderna said government ... said Moderna could not defeat case at early stage (Reuters) - Moderna Inc must face a patent infringement lawsuit over its COVID-19 vaccines, a federal judge in ...

(Reuters) -Moderna ... patents, a win in an ongoing COVID-19 vaccine dispute with Pfizer and BioNTech. The company has been locked in a legal battle with Pfizer-BioNTech over their COVID shot ...

Moderna said on Friday (May 17) the European Patent Office had upheld the validity of one of the company's key patents, a win in an ongoing Covid-19 vaccine dispute with Pfizer and BioNTech.

Moderna said that the European Patent Office had decided to maintain the validity of one of the company's key patents currently asserted against Pfizer and BioNTech in various European national ...